Active Contour Model for Image Segmentation with Dilated Convolution Filter

ACMs have been demonstrated to be highly suitable as image segmentation models for computer vision tasks. Among other ACM, the local region-based models show better performance because they extract the local information regarding intensity in the neighborhood and embed it into the energy minimization function to guide the active contour to the boundary of the desired object. However, the online segmentation of noisy and inhomogeneous is still a challenging task for local region-based ACM models. To overcome this challenge, the paper proposes a novel region-based active contour model, named active contour model with local dilated convolution filter (ACLD). The ACLD integrates local image information in the form of a signed pressure force function. Then, a Gaussian kernel is applied using dilated convolution instead of discrete convolution for regularizing the level set formulation. Finally, instead of using a constant stopping condition, the ACLD automatically stops at the object boundaries. The proposed model shows improved image segmentation results visually combined with less computational time in the case of synthetic and natural images compared with the state-of-the-art models. Further, on the ISIC2017 dataset, the ACLD yields segmentation results with the highest accuracy. </p

BRAIn: Bayesian Reward-conditioned Amortized Inference for natural language generation from feedback

Distribution matching methods for language model alignment such as Generation with Distributional Control (GDC) and Distributional Policy Gradient (DPG) have not received the same level of attention in reinforcement learning from human feedback (RLHF) as contrastive methods such as Sequence Likelihood Calibration (SLiC), Direct Preference Optimization (DPO) and its variants. We identify high variance of the gradient estimate as the primary reason for the lack of success of these methods and propose a self-normalized baseline to reduce the variance. We further generalize the target distribution in DPG, GDC and DPO by using Bayes' rule to define the reward-conditioned posterior. The resulting approach, referred to as BRAIn - Bayesian Reward-conditioned Amortized Inference acts as a bridge between distribution matching methods and DPO and significantly outperforms prior art in summarization and Antropic HH tasks.Comment: Accepted at ICML 2024 (main conference

Crisis Standard of Care: Management of Infantile Spasms during COVID‐19

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/156180/2/ana25792_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/156180/1/ana25792.pd

The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis

Background: The development of digital technologies and the evolution of open innovation approaches have enabled the creation of diverse virtual organizations and enterprises coordinating their activities primarily online. The open innovation platform titled "International Natural Product Sciences Taskforce" (INPST) was established in 2018, to bring together in collaborative environment individuals and organizations interested in natural product scientific research, and to empower their interactions by using digital communication tools. Methods: In this work, we present a general overview of INPST activities and showcase the specific use of Twitter as a powerful networking tool that was used to host a one-week "2021 INPST Twitter Networking Event" (spanning from 31st May 2021 to 6th June 2021) based on the application of the Twitter hashtag #INPST. Results and Conclusion: The use of this hashtag during the networking event period was analyzed with Symplur Signals (https://www.symplur.com/), revealing a total of 6,036 tweets, shared by 686 users, which generated a total of 65,004,773 impressions (views of the respective tweets). This networking event's achieved high visibility and participation rate showcases a convincing example of how this social media platform can be used as a highly effective tool to host virtual Twitter-based international biomedical research events

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.